However, given that the incidences of VTEs increase with age, the results did not encourage GnRH use in older patients or patients at advanced stages but emphasized critical concerns regarding the cardiac safety of GnRH therapy in all population of prostate cancer patients that include those who were younger or were at an early stage of cancer. The gene discussed is GNRH1; the disease is cancer.